Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease.
Grace CastroPatricia A MerkelHannah E GiclasAndrew GibulaGillian E AndersenLaurence M CorashJin Sying LinJennifer GreenVijaya KnightAdonis StassinopoulosPublished in: Transfusion (2018)
Amotosalen/UVA treatment more effectively inactivates T cells than the current standard of gamma irradiation (2500 cGy) for the prevention of TA-GVHD.